Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Journal article

BACKGROUND: Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody d...

Expand abstract

Authors: Keymeulen, B; Vandemeulebroucke, E; Ziegler, A; Mathieu, C; Kaufman, L

• Publication status: Published
• Journal: New England journal of medicine
• Volume: 352
• Issue: 25
• Pages: 2598-2608
• Publication date: 2005-06-01
• DOI: 10.1056/nejmoa043980
• EISSN: 1533-4406
• ISSN: 0028-4793
• Language: English
• Keywords: Hypoglycemic Agents; Antigens, CD3; Adolescent; Diabetes Mellitus, Type 1; Autoantibodies; Insulin; Child; Humans; Glucose Clamp Technique; Adult; Female; C-Peptide; Herpesviridae; Immunoglobulin G; Islets of Langerhans; Blood Glucose; Male